Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Monoclonal antibody successes in the clinic

Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Number of therapeutic mAbs entering clinical study per year (1980–2004).
Figure 2: Clinical phase transition percentages for therapeutic mAbs, according to FDA data.
Figure 3: Therapeutic categories for mAbs in clinical study.

References

  1. 1

    Reichert, J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19, 819–822 (2001).

    CAS  Article  Google Scholar 

  2. 2

    Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110–118 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3

    Reichert, J. & Pavolu, A. Monoclonal antibodies market. Nat. Rev. Drug Discov. 3, 383–384 (2004).

    CAS  Article  Google Scholar 

  4. 4

    Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).

    CAS  Article  Google Scholar 

  5. 5

    Milstein, C. The hybridoma revolution: an offshoot of basic research. Bioessays 21, 966–973 (1999).

    CAS  Article  Google Scholar 

  6. 6

    Morrison, S.L. et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).

    CAS  Article  Google Scholar 

  7. 7

    Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).

    CAS  Article  Google Scholar 

  8. 8

    Cole, S.P., Campling, B.G., Atlaw, T., Kozbor, D. & Roder, J.C. Human monoclonal antibodies. Mol. Cell. Biochem. 62, 109–120 (1984).

    CAS  Article  Google Scholar 

  9. 9

    Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311 (1986).

    CAS  Article  Google Scholar 

  10. 10

    Pasqualini, R. & Arap, W. Hybridoma-free generation of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 101, 257–259 (2004).

    CAS  Article  Google Scholar 

  11. 11

    Inglis, T.J.J. et al. Monoclonal antiendotoxin agent HA-1A (Centoxin). Lancet 341, 303 (1993).

    CAS  Article  Google Scholar 

  12. 12

    Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).

    CAS  Article  Google Scholar 

  13. 13

    Fleming, T. (ed.). Red Book (Thomson PDR, Montvale, New Jersey, 2004).

    Google Scholar 

  14. 14

    Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the assistance of the companies that provided survey data. We also thank H. Pujar for reviewing the manuscript and for providing helpful comments and suggestions.

Author information

Affiliations

Author notes

  1. Clark J. Rosensweig and Matthew C. Dewitz were summer interns at CSDD.

    Authors

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Reichert, J., Rosensweig, C., Faden, L. et al. Monoclonal antibody successes in the clinic. Nat Biotechnol 23, 1073–1078 (2005). https://doi.org/10.1038/nbt0905-1073

    Download citation

    Further reading

    Search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing